NASDAQ: CRME TSX: COM
VANCOUVER, May 20, 2014 /PRNewswire/ - Cardiome Pharma Corp. CRME COM today announced an agreement with AOP Orphan Pharmaceuticals AG, headquartered in Vienna, Austria, to commercialize AGGRASTAT® (tirofiban HCl) in selected European markets. AOP Orphan will be responsible for the commercialization of AGGRASTAT in the AOP Orphan countries. Under terms of the agreement, AOP Orphan has agreed to specific annual commercial goals for AGGRASTAT. Financial details of the agreement were not disclosed.
"We are pleased to expand our relationship with AOP Orphan to include AGGRASTAT in addition to BRINAVESS," said Karim Lalji, Cardiome's Chief Commercial Officer. "AGGRASTAT is an excellent fit with AOP's established portfolio of cardiovascular products. We are looking forward to working with AOP to sell AGGRASTAT and to implement Cardiome's commercialization strategy for this product."
"We are excited to partner and work with Cardiome to commercialize AGGRASTAT, the second Cardiome product in our cardiovascular portfolio," said Rudolf Widmann, Ph.D., CEO of AOP Orphan. "We are looking forward to selling AGGRASTAT to our existing customer base and to developing new customer relationships which will be key to the future growth of our cardiovascular franchise."
Key AOP Orphan countries for AGGRASTAT include: Austria, Hungary, Switzerland, and other Eastern European states.
About Cardiome Pharma Corp.
Cardiome Pharma Corp. is a specialty pharmaceutical company dedicated to
the development and commercialization of cardiovascular therapies that
will improve the quality of life and health of patients suffering from
heart disease. Cardiome has two marketed, in-hospital, cardiology
products, BRINAVESS™ (vernakalant IV), approved in Europe and other
territories for the rapid conversion of recent onset atrial
fibrillation to sinus rhythm in adults, and AGGRASTAT® (tirofiban HCl)
a reversible GP IIb/IIIa inhibitor indicated for the treatment of acute
coronary syndrome patients.
Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit our web site at www.cardiome.com.
About AOP Orphan Pharmaceuticals AG
AOP Orphan is a multinational Austrian company with a strong focus on
clinical research, development and commercialization of medicines for
rare and complex diseases. Supplying patients and medical specialists
with such medications requires the provision of extended services. Big
global companies encounter frequent problems in serving such market
segments optimally, a fact reflected in the rapid growth of AOP Orphan
as we provide individualized and customized services to meet and
accommodate for the needs of physicians and patients. AOP Orphan
provides its services across all Central Europe, Middle East & Asia.
Currently AOP Orphan is concentrating on orphan and complex diseases in
hematology/oncology, cardiology, pulmonology, intensive care medicine,
neurology and psychiatry.
Forward-Looking Statement Disclaimer
Certain statements in this news release contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 or forward-looking information under applicable
Canadian securities legislation that may not be based on historical
fact, including without limitation statements containing the words
"believe", "may", "plan", "will", "estimate", "continue", "anticipate",
"intend", "expect" and similar expressions. Forward- looking
statements may involve, but are not limited to, comments with respect
to our objectives and priorities for the remainder of 2014 and beyond,
our strategies or future actions, our targets, expectations for our
financial condition and the results of, or outlook for, our operations,
research and development and product and drug development. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results,
events or developments to be materially different from any future
results, events or developments expressed or implied by such
forward-looking statements. Many such known risks, uncertainties and
other factors are taken into account as part of our assumptions
underlying these forward-looking statements and include, among others,
the following: general economic and business conditions in the United
States, Canada, Europe, and the other regions in which we operate;
market demand; technological changes that could impact our existing
products or our ability to develop and commercialize future products;
competition; existing governmental legislation and regulations and
changes in, or the failure to comply with, governmental legislation and
regulations; availability of financial reimbursement coverage from
governmental and third-party payers for products and related
treatments; adverse results or unexpected delays in pre-clinical and
clinical product development processes; adverse findings related to the
safety and/or efficacy of our products or products; decisions, and the
timing of decisions, made by health regulatory agencies regarding
approval of our technology and products; the requirement for
substantial funding to expand commercialization activities; and any
other factors that may affect our performance. In addition, our
business is subject to certain operating risks that may cause any
results expressed or implied by the forward-looking statements in this
presentation to differ materially from our actual results. These
operating risks include: our ability to attract and retain qualified
personnel; our ability to successfully complete pre-clinical and
clinical development of our products; changes in our business strategy
or development plans; intellectual property matters, including the
unenforceability or loss of patent protection resulting from
third-party challenges to our patents; market acceptance of our
technology and products; our ability to successfully manufacture,
market and sell our products; the availability of capital to finance
our activities; and any other factors described in detail in our
filings with the Securities and Exchange Commission available at www.sec.gov and the Canadian securities regulatory authorities at www.sedar.com. Given these risks, uncertainties and factors, you are cautioned not to
place undue reliance on such forward-looking statements and
information, which are qualified in their entirety by this cautionary
statement. All forward-looking statements and information made herein
are based on our current expectations and we undertake no obligation to
revise or update such forward-looking statements and information to
reflect subsequent events or circumstances, except as required by law.
SOURCE Cardiome Pharma Corp.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.